LON:4BB 4basebio (4BB) Share Price, News & Analysis GBX 450 +15.00 (+3.45%) As of 03:13 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About 4basebio Stock (LON:4BB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get 4basebio alerts:Sign Up Key Stats Today's Range 420▼ 45050-Day Range 439.50▼ 58052-Week Range 420▼ 1,150Volume36 shsAverage Volume1,598 shsMarket Capitalization£69.68 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 1,600Consensus RatingBuy Company Overview 4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation. Read More 4basebio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall Score4BB MarketRank™: 4basebio scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus Rating4basebio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside Potential4basebio has a consensus price target of GBX 1,600, representing about 255.6% upside from its current price of GBX 450.Amount of Analyst Coverage4basebio has received no research coverage in the past 90 days.Read more about 4basebio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of 4basebio is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 4basebio is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for 4BB. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield4basebio does not currently pay a dividend.Dividend Growth4basebio does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for 4basebio this week, compared to 0 articles on an average week. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, 4basebio insiders have not sold or bought any company stock.Percentage Held by Insiders12.07% of the stock of 4basebio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions0.90% of the stock of 4basebio is held by institutions.Read more about 4basebio's insider trading history. Receive 4BB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4basebio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. 4BB Stock News Headlines4basebio strengthens leadership with new CFO and board reshuffle1 hour ago | tipranks.com4basebio Plc - 4basebio Launches Enzymatic ssDNA PlatformMay 11 at 3:10 PM | uk.finance.yahoo.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors. | American Alternative (Ad)4basebio Launches Enzymatic ssDNA PlatformMay 11 at 3:10 PM | markets.businessinsider.com4basebio announces major expansion to support the growing demand of RUO and HQ synthetic DNA with lease of an innovation hub and manufacturing facility in Cambridge, UKMarch 31, 2026 | markets.businessinsider.com4basebio Plc - Appointment of COOMarch 12, 2026 | uk.finance.yahoo.com4basebio Plc - Appointment of CCOMarch 4, 2026 | uk.finance.yahoo.com4basebio strengthens commercial leadership, promoting Christine Wolosin to Chief Commercial OfficerMarch 3, 2026 | markets.businessinsider.comSee More Headlines 4BB Stock Analysis - Frequently Asked Questions How have 4BB shares performed this year? 4basebio's stock was trading at GBX 600 on January 1st, 2026. Since then, 4BB stock has decreased by 25.0% and is now trading at GBX 450. How were 4basebio's earnings last quarter? 4basebio PLC (LON:4BB) announced its quarterly earnings data on Monday, September, 29th. The company reported ($50.00) EPS for the quarter. How do I buy shares of 4basebio? Shares of 4BB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of 4basebio own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4basebio investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), IQE (IQE) and Omega Diagnostics Group (ODX). Company Calendar Last Earnings9/29/2025Today5/13/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:4BB CIKN/A Webwww.4basebio.com Phone44 1223 967 943FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Price Target for 4basebioGBX 1,600 High Price TargetGBX 1,600 Low Price TargetGBX 1,600 Potential Upside/Downside+255.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)GBX (99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£9.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-231.29% Return on Assets-54.30% Debt Debt-to-Equity Ratio201.47 Current Ratio2.73 Quick Ratio3.52 Sales & Book Value Annual Sales£1.78 million Price / Sales39.17 Cash FlowGBX 27.99 per share Price / Cash Flow16.08 Book ValueGBX (41) per share Price / Book-10.98Miscellaneous Outstanding Shares15,485,000Free FloatN/AMarket Cap£69.68 million OptionableNot Optionable Beta1.09 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (LON:4BB) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersIs this AI lab Elon’s SpaceX lifeline?Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...Chaikin Analytics | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredThe system holding the dollar together is gone…Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredStarting This July: Hundreds of trillions of dollars at stakeAccording to The Wall Street Journal, a new wave of asset tokenization is sweeping global markets - and it cou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4basebio PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share 4basebio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
